References
Richards A, van den Maagdenberg AM, Jen JC, Kavanagh D, Bertram P, Spitzer D et al (2007) C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 39(9):1068–1070
Ophoff RA, DeYoung J, Service SK, Joosse M, Caffo NA, Sandkuijl LA et al (2001) Hereditary vascular retinopathy, cerebroretinal vasculopathy, and hereditary endotheliopathy with retinopathy, nephropathy, and stroke map to a single locus on chromosome 3p21.1-21.3. Am J Hum Genet Aug; 69(2):447–53
Andreoli CM, Miller JW (2007) Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 18(6):502–508
Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M (2008) Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246(12):1699–1705
Ciulla TA, Rosenfeld PJ (2009) Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 20(3):158–165
Neubauer AS, Kook D, Haritoglou C, Priglinger SG, Kampik A, Ulbig MW, Ceklic L (2007) Bevacizumab and retinal ischemia. Ophthalmology 114(11):2096
Chung EJ, Roh MI, Kwon OW, Koh HJ (2008) Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 28(7):957–963
Bonini-Filho M, Costa RA, Calucci D, Jorge R, Melo LA Jr, Scott IU (2009) Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. Am J Ophthalmol 147(6):1022–1030
Acknowledgments
The authors thank Stefanie Guthmann for excellent technical assistance.
Conflict of interest statement
The authors do not have any commercial interest in any of the materials and methods used in this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kernt, M., Gschwendtner, A., Neubauer, A.S. et al. Effects of intravitreal bevacizumab treatment on proliferative retinopathy in a patient with cerebroretinal vasculopathy. J Neurol 257, 1213–1214 (2010). https://doi.org/10.1007/s00415-010-5500-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-010-5500-0